Bone morphogenetic protein 7 and autologous bone graft in revision surgery for non-union after lumbar interbody fusion

[31] Helmig P(2008)Posterior lumbar interbody fusion using rhBMP-2 Eur Spine J 17 1735-1744

[32] Niedermann B(2006)Vertebral bone resorption after transforaminal lumbar interbody fusion with bone morphogenetic protein (rhBMP-2) J Spinal Disord Tech 19 483-486

[33] Eiskjoer SP(2011)Osteolysis in transforaminal lumbar interbody fusion with bone morphogenetic protein-2 Spine 36 672-676

[34] Bünger CE(2007)Vertebral osteolysis after posterior interbody lumbar fusion with recombinant human bone morphogenetic protein 2: a report of five cases Spine J 7 609-614

[35] Rihn JA(2011)Adjacent vertebral body osteolysis with bone morphogenetic protein use in transforaminal lumbar interbody fusion Spine J. 11 507-510

[36] Patel R(2011)Promoting fusion in minimally invasive lumbar interbody stabilization with low-dose bone morphogenic protein-2–but what is the cost? Spine J. 11 527-533

[37] Makda J(2009)Transforaminal interbody fusion and the “off label” use of recombinant human bone morphogenetic protein-2 Spine J. 9 667-669

[38] Hong J(2013)Transforaminal Lumbar Interbody Fusion With rhBMP-2 in Spinal Deformity, Spondylolisthesis, and Degenerative Disease-Part 2: BMP Dosage-Related Complications and Long-term Outcomes in 509 Patients Spine 38 1137-1145

[39] Anderson DG(1999)Recombinant bone morphogenetic protein-7 as an intracorporal bone growth stimulator in unstable thoracolumbar burst fractures in humans: preliminary results Eur Spine J 8 485-490

[40] Vaccaro AR(2003)Simple carrier matrix modifications can enhance delivery of recombinant human bone morphogenetic protein-2 for posterolateral spine fusion Spine 28 429-434

[31] Helmig P(2008)Posterior lumbar interbody fusion using rhBMP-2 Eur Spine J 17 1735-1744

[32] Niedermann B(2006)Vertebral bone resorption after transforaminal lumbar interbody fusion with bone morphogenetic protein (rhBMP-2) J Spinal Disord Tech 19 483-486

[33] Eiskjoer SP(2011)Osteolysis in transforaminal lumbar interbody fusion with bone morphogenetic protein-2 Spine 36 672-676

[34] Bünger CE(2007)Vertebral osteolysis after posterior interbody lumbar fusion with recombinant human bone morphogenetic protein 2: a report of five cases Spine J 7 609-614

[35] Rihn JA(2011)Adjacent vertebral body osteolysis with bone morphogenetic protein use in transforaminal lumbar interbody fusion Spine J. 11 507-510

[36] Patel R(2011)Promoting fusion in minimally invasive lumbar interbody stabilization with low-dose bone morphogenic protein-2–but what is the cost? Spine J. 11 527-533

[37] Makda J(2009)Transforaminal interbody fusion and the “off label” use of recombinant human bone morphogenetic protein-2 Spine J. 9 667-669

[38] Hong J(2013)Transforaminal Lumbar Interbody Fusion With rhBMP-2 in Spinal Deformity, Spondylolisthesis, and Degenerative Disease-Part 2: BMP Dosage-Related Complications and Long-term Outcomes in 509 Patients Spine 38 1137-1145

[39] Anderson DG(1999)Recombinant bone morphogenetic protein-7 as an intracorporal bone growth stimulator in unstable thoracolumbar burst fractures in humans: preliminary results Eur Spine J 8 485-490

[40] Vaccaro AR(2003)Simple carrier matrix modifications can enhance delivery of recombinant human bone morphogenetic protein-2 for posterolateral spine fusion Spine 28 429-434